Brief: Medivir: Positive Data From Remetinostat Phase II Study In Basal Cell Carcinoma Published In Clinical Cancer Research

Medivir AB

12/08/2021 14:52

Aug 12 (Reuters) - Medivir AB  MVIRb.ST :
    * POSITIVE DATA FROM THE REMETINOSTAT PHASE II STUDY IN
BASAL CELL
CARCINOMA PUBLISHED IN CLINICAL CANCER RESEARCH
    * OVERALL RESPONSE RATE (ORR), DEFINED AS PROPORTION OF
TUMORS
ACHIEVING MORE THAN 30% DECREASE IN LONGEST DIAMETER FROM
BASELINE TO WEEK 8, WAS 69.7% [90% CONFIDENCE INTERVAL (CI),
54%-82.5%]
    * ON PATHOLOGIC EXAMINATION, 54.8% OF TUMORS DEMONSTRATED
COMPLETE
RESOLUTION. NO SYSTEMIC ADVERSE EVENTS WERE REPORTED
    * NO SYSTEMIC ADVERSE EVENTS WERE REPORTED.

Source text for Eikon:  ID:nWkr7d5pyG 
Further company coverage:  MVIRb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))